Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.

J Headache Pain · 2024 · PMC10840250 · PMID 38311738

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

on the other hand, observed that lasmiditan 200 mg numerically surpassed rimegepant and ubrogepant but did not reach statistical significance [ 37 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.